An update on adenosine A2A-dopamine D2 receptor interactions: Implications for the function of G protein-coupled receptors

Current Pharmaceutical Design

Volumn 14, Issue 15, 2008, Pages 1468-1474

  Ferre S ^a   Quiroz, C ^a   Woods, A S ^a   Cunha, R ^b   Popoli, P ^c   Ciruela, F ^d   Lluis, C ^d   Franco, R ^d   Azdad, K ^e   Schiffmann, S N ^e  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adenosine A2A receptor; Basal ganglia disorders; Dopamine D2 receptor; Drug addiction; G protein coupled receptors; Receptor heteromers; Striatum

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENYLATE CYCLASE; ADENYLATE CYCLASE TYPE III; ADENYLATE CYCLASE TYPE IV; ADENYLATE CYCLASE TYPE V; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LEVODOPA; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; 4 AMINOBUTYRIC ACID; ENKEPHALIN; GUANINE NUCLEOTIDE BINDING PROTEIN;

BRAIN FUNCTION; DOWN REGULATION; DRUG DEPENDENCE; DRUG POTENTIATION; ENZYME ACTIVATION; EXTRAPYRAMIDAL SYNDROME; GENE EXPRESSION REGULATION; HUMAN; NERVE EXCITABILITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; STRIATE CORTEX; UPREGULATION; ADDICTION; ANIMAL; BASAL GANGLION; DRUG ANTAGONISM; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ADENYLATE CYCLASE; ANIMALS; BASAL GANGLIA; BASAL GANGLIA DISEASES; ENKEPHALINS; ENZYME ACTIVATION; GAMMA-AMINOBUTYRIC ACID; GTP-BINDING PROTEINS; HUMANS; NEURONS; PHOSPHORYLATION; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SUBSTANCE-RELATED DISORDERS;

EID: 47349126631     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784480108     Document Type: Review

References (77)

1. Snyder SH, Ferris CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000; 157: 1738-51.
2. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52
3. Schiffmann SN, Fisone G, Moresco R, Cunha R, Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007; 83: 277-92.
4. Ginés S, Hillion J. Torvinen M, Le Crom S, Casado V, Canela EI, et al. Dopamine D1 and adencisine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci. USA 2000; 97: 8606-11.
5. Ciruela F, Escriche M, Burgueno J, Angulo E, Casado V, Soloviev MM, et al. Metabotropic glutamate 1alpha, and adenosine Al receptors assemble into functionally interacting complexes. J Biol Chem 2001; 276: 18345-51.
6. Yoshioka K, Saitoh O, Nakata H. Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci USA 2001; 98: 7617-22
7. Ferre S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci USA 2002; 99: 11940-5.
8. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091-7.
9. Agnati LF, Ferré S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/ receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003; 55: 509-50.
10. Canals M, Marcellino D, Fanelli F. Ciruela F, de Benedetti P, Goldberg SR, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003; 278: 46741-9.
11. Kamiya T, Saitoh O, Yoshioka K, Nakata H. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 27; 306: 544-9.
12. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine Al-A2A nxqtor heteromers. J Neurosci 2006;26:2080-7.
13. Carriba P, Ortiz O. Patkar K, Justinova Z. Stroik J, Themann A, et al. Striatal adenosine A(2A) and cannabinoid CB(1) receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 2007; 32: 2249-59.
14. Ferré S. Ciruela F, Woods AS, Lluis C, Franco R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 2007; 30: 440-6.
15. Gerfen CR. Basal Ganglia. In: Paxinos G Ed, The rat nervous system. Amsterdam, Elsevier Academic Press 2004;445-508.
16. Ferré S, Agnati LF, Ciruela F, Lluis C, Woods AS, Foxe K, et al. Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res Rev 2007; 55: 55-67.
17. Ferré S, Borycz J, Goldberg SR, Hope BT, Morales M, Lluis C. et al. Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J Integr Neurosci 2005; 4: 445-64.
18. Newman EA. New roles for astrocytes: Regulation of synaptic transmission. Trends Neurosci 2003;26: 536-42.
19. Hertz L, Zielke R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 2004; 27: 735-43.
20. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005;310: 113-6.
21. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 1991;57: 1062-7.
22. Schiffmann SN, Vanderhaeghen JJ. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 1993; 13: 1080-7.
23. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997; 20: 482-7.
24. Ferré S, Ciruela F, Quiroz C, Lujan R, Popoli P, Cunha RA, et al. Adenosine receptor heteromers and their integrative role in striatal function. Scientific World Journal 2007; 7: 74-85.
25. Franco R, Casado V, Cortes A, Ferrada C, Mallol J, Woods A, et al. Basic concepts in G-protein-caupled receptor homo- and heteromerization. Scientific World Journal 2007; 7: 48-57.
26. 2 receptors. Anal Chem 2004; 76: 5354-63.
27. Woods AS, Ferré S. The amazing stability of the arginine-phosphate electrostatic interaction. J Proteome Res 2005; 4: 1397-402.
28. Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991; 88: 7238-41.
29. 2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol 1996; 316: 325-31.
30. Dixon AK, Widdowson L, Richardson PJ. Desensitisation of the adenosine Al receptor by the A2A receptor in the rat striatum. J Neurochem 1997; 69: 315-21.
31. 2 receptors in CHO cells co-transfected with the two receptors. Biochem Pharmacol 1999; 58: 1035-45.
32. 2 receptor-induced responses in stably cotransfected human neuroblastoma cells. J Neurochem 2000; 74; 432-9.
33. 2 receptors for dopamine in human striatum. NeuroReport 2001; 12: 1831-4.
34. Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, et al. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 2003; 28: 1317-27.
35. Ferré S, O'Connor WT, Fuxe K, Ungerstedt U. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J Neurosci 1993; 13: 5402-6.
36. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 1994; 63: 765-73.
37. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-rcceptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228-35.
38. Ferré S, Herrera-Marschitz M, Grabowska-Andégn M, Ungerstedt U, Casas M, Andén N-E. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit a D2-mediated behaviour in short-term reserpinized mice. Eur J Pharmacol 1991; 192: 30-5.
39. Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Ungerstedt U, Casas M, Andén N-E. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 1991; 192:36-42.
40. 2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 1998; 347: 153-8.
41. 2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 2000; 12: 4033-7.
42. Ferré S, Popoli P, Gimenez-Llort L, Rimondini R, Müller CE, Stromberg I, et al. Adenosine/dopamine interaction: Implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001; 7: 235-41.
43. Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience 1992; 51: 501-12.
44. Muller CE, Ferré S. Blocking striatal adenosine A2A receptors: A new strategy for basal ganglia disorders. Recent Pat CNS Drug Disc 2007; 2: 1-21.
45. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 2000; 97: 1856-60.
46. Hakansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 2006; 96: 482-8.
47. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 2007; 104: 654-9.
48. Banères JL, Parello J. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol 2003; 329: 815-29.
49. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A. Organization of the G protcin-coupled receptors rhodopsin and opsin in native membranes. J Piol Chem 2003; 278: 21655-62.
50. Herrick-Davis K, Grinde E, Harrigan TJ, Mazurkiewicz JE. Inhibition of serotonin 5-hydroxytryptamine2c receptor function through heterodimerization: Receptor dimers bind two molecules of ligand and one G-protein. J Biol Chem 2005; 280: 40144-51.
51. Franco R, Casado V, Mallol J, Ferrada C, Ferré S, Fuxe K, et al. The "two-state dimer receptor model". A general model for receptor dimers. Mol Pharmacol 2006; 69: 1905-12.
52. Casado V, Cortes A, Ciruela F, Mallol J, Ferré S, Lluis C, et al. Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: The receptor-dimer cooperativity index. Pharmacol Ther 2007; 116: 343-54.
53. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 1998; 80: 231-64.
54. Voss T, Wallner E, Czemilofisky AP, Freissmuth M. Amphipathic alpha-helical structure does not predict the ability of receptor-derived synthetic peptides to interact with guanine nucleotide-binding regulatory proteins. J Biol Chem 1993; 268: 4637-42.
55. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem 2000; 275: 32672-80.
56. Liu Y, Buck DC, Macey TA, Lan H, Neve KA. Evidence that calmodulin binding to the dopamine P2 receptor enhances receptor signaling. J Recept Signal Transduct Res 2007; 27: 47-65.
57. Nishi A, Liu F, Matsuyama S, Hamada M, Higashi H, Nairn AC, et al. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci USA 2003; 100: 1322-7.
58. 2A receptors. Neuropsychopharmacology 2001; 25: 505-13.
59. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarazchild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 2005; 25: 10414-19.
60. 2 receptors. Neurosci Lett 2002; 324: 154-8.
61. Lee KW, Hong JH, Choi IY, Che Y, Lee JK, Yang SD, et al. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci 2002; 22: 7931-40.
62. Yao L, Arolfo MP, Dohrman DP, Jiang Z, Fan P, Fuchs S, et al. Betagamma dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell 2002; 109: 733-43.
63. Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SMO, Huang ZL, et al. Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptivc circuitry. Implications for drug addiction, sleep and pain. Prog Neurobiol 2007; 83: 332-47.
64. Blumer JB, Cismowski MJ, Sato M, Lanier SM, AGS proteins: receptor-independent activators of G-protrin signaling. Trends Pharmacol Sci 2005; 26: 470-6.
65. Chem Y. Regulation of anenylyl cyclase in the central nervous system. Cell Signal 2000; 12: 195-204.
66. Bowers MS, McFarland K, Lake W, Peterson YK, Lapish CC, Gregory ML, et al. Activator of G protein signaling 3: A gatekeeper of cocaine sensitization and drug seeking. Neuron 2004; 42: 269-81.
67. Yao L. McFarland K, Fan P, Jiang Z, Inoue Y, Diamond I. Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-secking behavior. Proc Natl Acad Sci USA 2005; 102: 8746-51.
68. Mayfield RD, Suzuki F, Zahniser NR. Adenosine A2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J Neurochem 1993; 60: 2334-7.
69. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study. Neuroscience 2000; 100: 53-62.
70. Shindou T, Nonaka H, Richardson PJ, Mori A, Kase H, Ichimura M. Presynaptic adenosine A(2A) receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol 2002; 136: 296-302.
71. Leenders AG, Sheng ZH. Modulation of neurotransmitter release by the second messenger-activated protein kinases: Implications for presynaptic plasticity. Pharmacol Ther 2005; 105: 69-84.
72. Gubitz AK, Widdowson L, Kurokawa M, Kirkpatrick KA, Richardson PJ. Dual signalling by the adenosine A2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J Neurochem 1996; 67: 374-81.
73. Okada M, Nutt DJ, Murakami T, Zhu G, Kamata A, Kawata Y, et al. Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci 2001; 21: 628-40.
74. Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M. Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. Exp Neurol 2006; 202: 255-7.
75. Tanganelli S, Sandager Nielsen K, Ferraro L, Antonelli T, Kehr J, Franco R, et al. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's disease. Parkinsonian Relat Disord 2004; 10: 273-80.
76. Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA. Co-localization and functional interaction between adenosine A and metabotropic group 5 receptors in glutamatergic time terminals of the rat striatum. J Neurochem 2005; 92: 433-41.
77. Tozzi A, Tscherter A, Belcastro V, Tantucci M, Costa C, Picconi B, et al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neumpharmacology 2007; 53: 783-9.